GO
Loading...

Merck & Co Inc

More

  • Midday movers: Apple, McDonald's, NeuStar & More Monday, 9 Jun 2014 | 12:01 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • *Apple sees heavy trading following stock split. NEW YORK, June 9- U.S. stocks advanced on Monday, boosted by a number of major acquisition deals, though gains were slight with key indexes continuing to hover around records. While Wall Street's upward trend looks intact, traders may need new catalysts to bid the market up further lest the momentum runs out of steam.

  • Behind the Merck-Idenix deal     Monday, 9 Jun 2014 | 10:06 AM ET

    Merck is buying Idenix Pharmaceuticals for $3.85 billion in a deal that has already been approved by the boards of both companies, reports CNBC's Meg Tirrell.

  • Merck to buy Idenix to boost hepatitis C pipeline Monday, 9 Jun 2014 | 9:42 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Drug giant Merck said it would purchase Idenix Pharmaceuticals for $3.85 billion, a deal already approved by both companies' board of directors.

  • Stock futures point to early retreat from records Monday, 9 Jun 2014 | 9:07 AM ET

    U.S. stock index futures pointed to a flat-to-lower open on Wall Street on Monday, despite upbeat data from China and Japan.

  • Merck buys Idenix for $3.85 billion     Monday, 9 Jun 2014 | 9:06 AM ET

    Merck announced it will buy biotechnology company Idenix for $24.50 per share in cash, with the "Squawk on the Street" crew. Jim Cramer explains why he wasn't eyeing phase 2 data closely enough.

  • *Apple may see heavy action following stock split. NEW YORK, June 9- U.S. stock index futures pointed to modest losses at the open on Monday, as a rash of corporate deals weren't enough reason for investors to keep buying following a rally that has taken major indexes to repeated record highs.

  • Early movers: TSN, AAPL, TIME, MRK & more Monday, 9 Jun 2014 | 7:54 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Merck acquires Idenix     Monday, 9 Jun 2014 | 7:31 AM ET

    Merck announced it will buy biotechnology company Idenix for $24.50 per share in cash, with the "Squawk Box" crew.

  • June 6- An infectious disease expert and former head dealmaker at Merck& Co is racing against his ex-employer and other drugmakers to develop a treatment for a germ that ravages the colon and kills as many as 14,000 Americans each year.

  • Merck proud to be a US-based company: CEO Wednesday, 4 Jun 2014 | 8:52 AM ET
    Ken Frazier, president and CEO of Merck.

    But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.

  • Merck CEO: We're proud to be American     Wednesday, 4 Jun 2014 | 8:06 AM ET

    Merck chief Kenneth Frazier does want the government to change the corporate tax code to help U.S.-based companies.

  • Merck's new weapon in fight against cancer     Wednesday, 4 Jun 2014 | 8:03 AM ET

    Ken Frazier, Merck chairman & CEO, discusses the latest immune drug for treating melanoma and lung cancer. Also Frazier weighs in on the high cost of drugs.

  • CHICAGO, June 3- AstraZeneca Plc, in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world's largest meeting of cancer doctors.

  • *Expects 2nd- qtr adj profit/share $0.12- $0.13 vs est $0.21. *Expects revenue $250- $252 mln vs est $267.5 mln. Tibco, whose customers include Delta Air Lines Inc, FedEx Corp and Merck& Co Inc, estimated adjusted earnings of 12- 13 cents per share for the quarter ended June 1.

  • CHICAGO, June 3- AstraZeneca Plc, in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world's largest meeting of cancer doctors.

  • FRANKFURT, June 3- German drugmaker Bayer AG said on Tuesday its chief executive Marijn Dekkers is to step down at the end of 2016 for family reasons and the group's chief financial officer is moving over later this year to take charge of strategy to ensure continuity. Marijn Dekkers will be extended by just two years on expiration of the initial five-year period.

  • Why these 3 biotech stocks are making big moves Monday, 2 Jun 2014 | 9:44 AM ET

    Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.

  • Merck's findings on melanoma drug     Monday, 2 Jun 2014 | 9:00 AM ET

    CNBC's Meg Tirrell and Roger Perlmutter, Merck Research Laboratories president, discuss the latest data on advanced melanoma and which new drugs are in Merck's pipeline.

  • Early movers: BRCM, MYL, GOOG, Z & more Monday, 2 Jun 2014 | 7:37 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.